The short version
- Why people research itDepression and delayed sleep phase through melatonin-receptor agonism and 5-HT2C blockade; carries a liver-monitoring requirement.
- What the evidence isTwo positive placebo-controlled depression trials and one negative add-on trial.
- What to watchYellow skin or eyes, dark urine or pale stools, or right-sided upper abdominal pain (liver signs).
How Agomelatine works
A two-handed drug: it is a potent agonist at the melatonin MT1 and MT2 receptors that set the body clock, and a neutral antagonist at the serotonin 5-HT2C receptor, which normally restrains dopamine and noradrenaline release in the frontal cortex. The pharmacology review argues the antidepressant effect comes from the two actions working together, partly because MT1 and MT2 form complexes with 5-HT2C at the cell level. Together they re-time sleep and wake and raise hippocampal cell proliferation and survival in animals. It does not raise serotonin the way an SSRI does, which is why it is described as mechanistically different from the standard antidepressant classes.
The mechanism is a synergy argument. It is a potent MT1/MT2 agonist and a neutral 5-HT2C antagonist, and the receptors form complexes that may explain how the two actions combine, with raised hippocampal proliferation and survival in animals (Guardiola-Lemaitre 2014).
The pharmacology review argues the antidepressant effect comes from the two actions working together, partly because MT1 and MT2 form complexes with 5-HT2C at the cell level. Together they re-time sleep and wake and raise hippocampal cell proliferation and survival in animals. It does not raise serotonin the way an SSRI does, which is why it is described as mechanistically different from the standard antidepressant classes.
- Oral
Research on Agomelatine5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Human (placebo-controlled depression trials, one negative add-on trial, a small sleep-phase trial); pharmacovigilance for liver injury; mechanism reviews.
Human clinical evidence
Two positive placebo-controlled depression trials and one negative add-on trial. A higher response rate and a faster first response than placebo (Kennedy 2006). Response, sleep quality and quality of life. Added to an SSRI or SNRI in 123 non-responders, it did no better than placebo (Ju 2025).
A small randomized sleep-phase study. Four weeks shifted the sleep-wake rhythm earlier in 60 young adults with delayed sleep-wake phase disorder; adding CBT improved sleep quality and daytime sleepiness further. It was non-blinded and had no placebo arm (Yu 2023).
Correlative data
The liver signal is real and was acted on by a regulator. Pooled trial data show more patients with transaminases above three times the upper limit than on placebo, and the European regulator added liver-test contraindications and a warning on strong CYP1A2 inhibitors (Gahr 2014). A worldwide pharmacovigilance analysis found a clearly raised reporting ratio for liver injury (Gahr 2015). Neither can give an incidence, and the cases are idiosyncratic.
How the mechanism reads
The mechanism is a synergy argument. It is a potent MT1/MT2 agonist and a neutral 5-HT2C antagonist, and the receptors form complexes that may explain how the two actions combine, with raised hippocampal proliferation and survival in animals (Guardiola-Lemaitre 2014). That is why it behaves unlike an SSRI, and it is a reasoned account, not a proven one.
MechanisticThe predicted downside is the liver, plus drug interaction. The risk follows from how the drug is cleared (CYP1A2), so anything that blocks that route raises exposure. What is not known is who is at risk before it happens.
Mechanistic
Agomelatine safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Any liver disease, raised liver enzymes or heavy alcohol use, since the drug carries a documented rate of transaminase elevation and rare severe liver injury.
- Taking a strong CYP1A2 inhibitor, which raises the level of the drug the liver has to clear.
- Bipolar disorder or a history of mania, because an antidepressant can tip mood the wrong way.
- Pregnancy or breastfeeding, where there is no adequate safety record.
- Driving or shift work that depends on alertness, because it re-times sleep and can cause daytime drowsiness.
What’s expected
- Mild nausea, headache or dizziness early on are the usual complaints.
- Sleepier evenings and a shifted sleep-wake rhythm, which is its melatonin action working.
Watch for
- Yellow skin or eyes, dark urine or pale stools, or right-sided upper abdominal pain (liver signs).
- Worsening mood, agitation or thoughts of self-harm, especially in the first weeks.
- Unusual daytime drowsiness or a rhythm that has shifted too far.
Labs that tell you it’s working
- Alanine and aspartate aminotransferase (in the Comprehensive Metabolic Panel): the main safety readout, before and during use.
- Cortisol: the clock-linked stress hormone that melatonin timing should move.
- Vitamin D: low levels travel with low mood and confound the response.
Melatonin-receptor agonist and 5-HT2C antagonist antidepressant; the safety read is driven by a documented transaminase signal, CYP1A2 clearance and mood-disorder cautions. PMID 25255870 PMID 25650773 PMID 20361916
Bloodwork to runHow you would know it is working: 5 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Agomelatine FAQ4 common questions
- Is Agomelatine approved for human use?
- No. Agomelatine is a research compound.
- What is Agomelatine researched for?
- Depression and delayed sleep phase through melatonin-receptor agonism and 5-HT2C blockade; carries a liver-monitoring requirement.
- Which labs show whether it's doing anything?
- Alanine and aspartate aminotransferase; Cortisol; Vitamin D: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Agomelatine: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



